Chimerix, Inc. (NASDAQ:CMRX) Short Interest Update

Chimerix, Inc. (NASDAQ:CMRX - Get Free Report) was the recipient of a large decrease in short interest in October. As of October 31st, there was short interest totalling 1,520,000 shares, a decrease of 12.6% from the October 15th total of 1,740,000 shares. Based on an average daily trading volume, of 460,100 shares, the days-to-cover ratio is currently 3.3 days. Currently, 1.9% of the shares of the stock are short sold.

Chimerix Trading Down 4.3 %

Shares of Chimerix stock traded down $0.04 during trading hours on Friday, reaching $0.86. 689,133 shares of the company's stock were exchanged, compared to its average volume of 250,829. Chimerix has a 52-week low of $0.75 and a 52-week high of $1.30. The company has a fifty day moving average of $0.90 and a 200-day moving average of $0.91. The firm has a market capitalization of $77.34 million, a price-to-earnings ratio of -0.91 and a beta of 1.13.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on the company. StockNews.com raised Chimerix from a "sell" rating to a "hold" rating in a report on Wednesday, August 21st. HC Wainwright reissued a "buy" rating and issued a $11.00 target price on shares of Chimerix in a research note on Monday, November 11th. Finally, Wedbush reaffirmed an "outperform" rating and set a $6.00 price target on shares of Chimerix in a research note on Thursday, November 7th.

Hedge Funds Weigh In On Chimerix

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Chimerix by 66.8% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 344,712 shares of the biopharmaceutical company's stock valued at $321,000 after purchasing an additional 138,098 shares in the last quarter. Valeo Financial Advisors LLC lifted its position in Chimerix by 566.9% during the third quarter. Valeo Financial Advisors LLC now owns 81,766 shares of the biopharmaceutical company's stock valued at $76,000 after buying an additional 69,505 shares in the last quarter. Marshall Wace LLP purchased a new stake in Chimerix during the second quarter worth approximately $137,000. Acadian Asset Management LLC raised its stake in shares of Chimerix by 15.5% in the 1st quarter. Acadian Asset Management LLC now owns 2,174,813 shares of the biopharmaceutical company's stock valued at $2,304,000 after acquiring an additional 291,981 shares during the period. Finally, Koshinski Asset Management Inc. acquired a new position in shares of Chimerix during the 1st quarter valued at $42,000. Institutional investors and hedge funds own 45.42% of the company's stock.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.